Biocon Limited has informed the Exchange regarding a press release dated April 10, 2025, titled "Biocon Biologics Announces U.S. FDA Approval for Jobevne , Biosimilar Bevacizumab, Expanding Its Oncology Portfolio".
Biocon Limited has informed the Exchange regarding a press release dated April 10, 2025, titled "Biocon Biologics Announces U.S. FDA Approval for Jobevne , Biosimilar Bevacizumab, Expanding Its Oncology Portfolio".